Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

ABSTRACT:

SUBMITTER: Kremsner PG 

PROVIDER: S-EPMC8610426 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature